AI Market Mood: Stock Dashboard
TSHA
Fundamental
Company: Taysha Gene Therapies Inc
Sector: Healthcare
Industry: Biotechnology
Country: USA
Exchange: NASD
Index: RUT
P/E: -
EPS (ttm): -0.36
Insider Own: 17.89%
Shs Outstand: 261.53M
Perf Week: 1.80%
Market Cap: 741.44M
Forward P/E: -
EPS next Y: -0.38
Insider Trans: 1.63%
Shs Float: 213.50M
Perf Month: 35.00%
Income: -86.77M
PEG: -
EPS next Q: -0.08
Inst Own: 62.25%
Short Float: 12.29%
Perf Quarter: 64.83%
Sales: 7.22M
P/S: 102.69
EPS this Y: 9.34%
Inst Trans: 0.79%
Short Ratio: 7.70
Perf Half Y: 15.48%
Book/sh: 0.27
P/B: 10.56
EPS next Y Percentage: -15.88%
ROA: -59.56%
Short Interest: 26.24M
Perf Year: -28.95%
Cash/sh: 0.45
P/C: 6.33
EPS next 5Y: 11.90%
ROE: -159.34%
52W Range From: 1.05
52W Range To: 4.32
Perf YTD: 63.87%
Dividend Est.: -
P/FCF: -
EPS past 5Y: -63.99%
ROIC: -75.53%
52W High: -34.38%
Beta: 1.02
Dividend TTM: -
Quick Ratio: 5.35
Sales past 5Y: -
Gross Margin: 83.57%
52W Low: 170.00%
ATR (14): 0.24
Dividend Ex-Date: -
Current Ratio: 5.35
EPS Y/Y TTM: 69.32%
Oper. Margin: -1158.80%
RSI (14): 62.43
Volatility W: 1.94%
Volatility M: 4.63%
Employees: 73
Debt/Eq: 1.13
Sales Y/Y TTM: -48.97%
Profit Margin: -1201.08%
Recom: 1.09
Target Price: 7.75
Option/Short: Yes / Yes
LT Debt/Eq: 1.09
EPS Q/Q: 23.17%
Payout: -
Rel Volume: 0.42
Prev Close: 2.84
Sales Surprise: 23.16%
EPS Surprise: 8.68%
Sales Q/Q: -32.51%
Earnings: May 15 BMO
Avg Volume: 3.41M
Price: 2.84
SMA20: 5.17%
SMA50: 37.59%
SMA200: 44.25%
Trades:
Volume: 1,333,819
Change: -0.18%
Technical:
Latest News:
Needham & Company LLC Reiterates Buy Rating for Taysha Gene Therapies (NASDAQ:TSHA) somewhat bullish
TSHA
Summary: Taysha Gene Therapies received reiterations of 'buy' ratings from analysts at Needham & Company LLC and other firms, with price targets ranging from $7.00 to $9.00, indicating a potential upside of 76.32%. The company's earnings report exceeded consensus estimates, with a positive earnings per share and revenue results.
Full article2024-06-17T12:20:26Z
Hasbro Citigroup BofA Securities Weil, Gotshal & Manges Crav... - Law.com neutral
HAS
Summary: Hasbro completes a $500 million debt offering advised by Cravath, Swaine & Moore and underwriters BofA Securities and Citigroup, due 2034.
Full article2024-05-17T15:06:39Z